NO20042927L - Behandling av glioblastom med thymosin-alfa-1 - Google Patents

Behandling av glioblastom med thymosin-alfa-1

Info

Publication number
NO20042927L
NO20042927L NO20042927A NO20042927A NO20042927L NO 20042927 L NO20042927 L NO 20042927L NO 20042927 A NO20042927 A NO 20042927A NO 20042927 A NO20042927 A NO 20042927A NO 20042927 L NO20042927 L NO 20042927L
Authority
NO
Norway
Prior art keywords
thymosin
glioblastoma
treatment
alpha
alpha1
Prior art date
Application number
NO20042927A
Other languages
English (en)
Norwegian (no)
Inventor
Jack R Wands
Suzanne La Monte
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Publication of NO20042927L publication Critical patent/NO20042927L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2292Thymosin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20042927A 2001-12-10 2004-07-08 Behandling av glioblastom med thymosin-alfa-1 NO20042927L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33714901P 2001-12-10 2001-12-10
PCT/US2002/039329 WO2003049697A2 (en) 2001-12-10 2002-12-10 Treatment of glioblastoma with thymosin-alpha 1

Publications (1)

Publication Number Publication Date
NO20042927L true NO20042927L (no) 2004-09-09

Family

ID=23319320

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042927A NO20042927L (no) 2001-12-10 2004-07-08 Behandling av glioblastom med thymosin-alfa-1

Country Status (22)

Country Link
US (1) US20060166870A1 (ru)
EP (1) EP1461063B1 (ru)
JP (1) JP2005516910A (ru)
KR (2) KR20100029844A (ru)
CN (1) CN1615147A (ru)
AT (1) ATE356628T1 (ru)
AU (1) AU2002357115B2 (ru)
BR (1) BR0214848A (ru)
CA (1) CA2469595A1 (ru)
DE (1) DE60218896T2 (ru)
DK (1) DK1461063T3 (ru)
EA (1) EA005822B1 (ru)
ES (1) ES2283653T3 (ru)
IL (1) IL162434A0 (ru)
MX (1) MXPA04005585A (ru)
NO (1) NO20042927L (ru)
NZ (1) NZ533942A (ru)
PL (1) PL370829A1 (ru)
PT (1) PT1461063E (ru)
SI (1) SI1461063T1 (ru)
UA (1) UA77999C2 (ru)
WO (1) WO2003049697A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2288118B1 (es) 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
CN108226016A (zh) * 2018-01-12 2018-06-29 浙江普罗亭健康科技有限公司 肿瘤免疫细胞亚群精准分型的质谱流式检测试剂盒
CN112147326B (zh) * 2020-09-04 2022-04-08 北京大学 一种肿瘤免疫细胞亚群分型精准检测试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148786A (en) * 1978-06-26 1979-04-10 American Home Products Corporation Analgesic polypeptide
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
IT1238231B (it) * 1989-12-18 1993-07-12 Consiglio Nazionale Ricerche Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
FR2793684B1 (fr) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US6462017B1 (en) * 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients

Also Published As

Publication number Publication date
EP1461063A4 (en) 2005-08-31
IL162434A0 (en) 2005-11-20
AU2002357115B2 (en) 2007-12-13
AU2002357115A1 (en) 2003-06-23
SI1461063T1 (sl) 2007-08-31
UA77999C2 (en) 2007-02-15
ATE356628T1 (de) 2007-04-15
BR0214848A (pt) 2004-11-09
CN1615147A (zh) 2005-05-11
KR20040091611A (ko) 2004-10-28
PT1461063E (pt) 2007-06-18
EP1461063A2 (en) 2004-09-29
WO2003049697A2 (en) 2003-06-19
EP1461063B1 (en) 2007-03-14
MXPA04005585A (es) 2005-03-23
DE60218896D1 (de) 2007-04-26
WO2003049697A3 (en) 2004-01-15
ES2283653T3 (es) 2007-11-01
PL370829A1 (en) 2005-05-30
DE60218896T2 (de) 2007-09-20
NZ533942A (en) 2007-01-26
EA005822B1 (ru) 2005-06-30
KR20100029844A (ko) 2010-03-17
US20060166870A1 (en) 2006-07-27
EA200400755A1 (ru) 2004-12-30
JP2005516910A (ja) 2005-06-09
DK1461063T3 (da) 2007-05-21
CA2469595A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
ECSP024382A (es) Inhibidores de proteasa de serina
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
CY1111640T1 (el) Μονοκυκλικοι ετεροκυκλοι ως αναστολεις κινασων
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
PT1347971E (pt) Inibidores tiazolilicos de tirosina-cinases da familia tec
BR0213981A (pt) Fotoiniciadores difuncionais
DE60042401D1 (de) Fab-i inhibitoren
BR0209149A (pt) Ftalazinonas
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
DE60105418D1 (de) Serinprotease-inhibitoren
NO20033959D0 (no) Benzimidazoler som er nyttige i behandling av seksuell dysfunksjon
SE0302304D0 (sv) Novel compounds
DK1392355T3 (da) Anvendelse af proteasominhibitorer tilbehandling af öjentörhedslidelser
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
NO20042927L (no) Behandling av glioblastom med thymosin-alfa-1
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
SE0302361D0 (sv) Inhibering av upptagning av monoamin
DE60110124D1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
TR200200169T2 (tr) IL-18 inhibitörlerinin kullanımı.
DE60124148D1 (de) Kalzilytische verbindungen
DE60219788D1 (de) Tetrazyklische verbindungen als pde5-inhibitoren
DK1042288T3 (da) Tripeptidyl-peptidase inhibitorer
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application